Main Organiser

Julius Centre University of Malaya

Co-organiser

Department of Social and Preventive Medicine, Faculty of Medicine, University of Malay

Supported by

University of Malaya

COMPARATIVE EFFECTIVENESS OF ARIPIPRAZOLE AND ZIPRASIDONE IN THE IMPROVEMENT OF METABOLIC SYNDROME COMPONENTS AND ATHEROGENIC DYSLIPIDEMIA IN SCHIZOPHRENIA PATIENTS: A RANDOMIZED, DOUBLE-BLIND, 6-MONTH STUDY

Author

Said MA, Sulaiman AH, Habil MH, Bulgiba AM

Institution

University of Malaya

Abstract

Objectives: To determine improvement of metabolic syndrome components and lipid profiles when previously treated with other antipsychotics.

Methods: A 6-month randomized double-blind clinical trial was conducted at four mental institutions and four general hospitals in Malaysia. 175 patients participated in the study. Metabolic measurements for waist circumference, blood pressure, fasting blood sugar, HDL, triglycerides, total cholesterol and LDL were taken. The definition of metabolic syndrome components were based on Modified National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) with Asian values for waist circumference.

Results: For metabolic syndrome components and dyslipidemia, there were significant difference in Least Squares mean change for multiple comparisons with Bonferonni correction p< 0.008 in waist circumference and total cholesterol for study visit 1 to 6 months between aripiprazole and ziprasidone. For MMRM analysis of metabolic syndrome components and dyslipidemia, there were statistically significant in the time effect for waist circumference and total cholesterol. These indicate significant reductions in LS mean change over time for both parameters. However there was no statistically significant for intervention x time interaction effect for all parameters.

Conclusion: Aripiprazole and ziprasidone were equally effective in the improvement of waist circumference and total cholesterol level in schizophrenia patients.